On Tuesday, 6th of June Konstantin von Schulthess, CFO and founder of CDR-Life, will talk about the biopharmaceutical company CDR-Life.
CDR-Life was founded in 2017 by a team of drug developers and biotech entrepreneurs with a mission to develop a next generation of superior T cell engaging therapies against solid and liquid tumours. CDR-Life is a biotherapeutics company developing novel therapies harnessing the power of the immune system. CDR-Life has developed the unique M-gager® technology to generate MHC-specific antibody-based T cell engagers that target highly tumour-specific intracellular antigens with unparalleled specificity. Their antibody fragment based MHC T cell engager has the promise of developing new immunotherapies with high tumor cell killing potency, longer duration of effect, and lower risk of immune-related adverse effects.
